Journal Information
Vol. 16. Issue 1.
Pages 74-77 (January - February 2012)
Share
Share
Download PDF
More article options
Vol. 16. Issue 1.
Pages 74-77 (January - February 2012)
Open Access
Expression of immunohistochemical markers in patients with AIDS-related lymphoma
Visits
3153
Luciana Barretoa,
Corresponding author
lubarreto@hotmail.com

Corresponding author at: Rua Santa Clara, 219/902, 22041-011, Rio de Janeiro Brazil.
, Denize Azambujaa, José Carlos de Moraisb
a Hematology, Oncology and Pathology Services, Instituto Nacional de Câncer, Rio de Janeiro, Brazil
b Hematology and Pathology Services, University Hospital, Universidade Federal do Rio de Janeiro, Brazil
This item has received

Under a Creative Commons license
Article information
Abstract
Bibliography
Download PDF
Statistics
Abstract

AIDS-related lymphomas (ARL) present high biological heterogeneity. For better characterization of this type of lymphoma, the objectives of the present study were to evaluate the expression of immunohistochemical markers of cell differentiation (CD10, Bcl-6, MUM-1) and determine cell origin profile according to Hans’ classification of diffuse large B-cell lymphoma in AIDS patients. This study included 72 consecutive patients with ARL diagnosed at the University Hospital, Universidade Federal do Rio de Janeiro (UFRJ) and at the Brazilian Instituto Nacional de Câncer (INCA) from 2000 to 2006. The morphologic distribution of the lymphomas was the following: 61% were diffuse large B-cell lymphomas (DLBCLs), 15% were Burkitt's lymphomas, 13% were plasmablastic lymphomas, 10% were high-grade lymphomas and 1% was follicular lymphoma. The positivity for each immunohistochemical marker in DLBCLs, Burkitt's lymphoma and plasmablastic lymphoma was respectively: CD20, 84%, 100%, and 0; CD10, 55%, 100%, and 0; Bcl-6, 45%, 80%, and 0; MUM-1, 41%, 20%, and 88%. A higher positivity of CD20 (84% × 56%, p=0.01) was found in DLBCL compared to non-DLBCL; in Burkitt's lymphomas a higher positivity of CD10 (100% × 49%, p=0.04) and Bcl-6 (80% × 39%, p=0.035) were found compared to non-Burkitt's lymphomas. Germinal center (GC) profile was detected in 60% of DLBCLs. Our study suggests particular findings in ARL, as the most frequent phenotype was GC, different from HIV-negative patients.

Keywords:
AIDS related-lymphoma
AIDS
Full text is only aviable in PDF
References
[1.]
U. Tirelli, M. Spina, G. Gaidano, et al.
Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy.
AIDS, 14 (2000), pp. 1675-1688
[2.]
A. Gucalp, A. Noy.
Spectrum of HIV lymphomas 2009.
Curr Opin Hematol, 17 (2010), pp. 362-367
[3.]
A.A. Alizadeth, M.B. Eisen, R.E. Davis, et al.
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.
Nature, 403 (2000), pp. 503-511
[4.]
C.P. Hans, D.D. Weisenburger, T.C. Greiner, et al.
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.
Blood, 103 (2004), pp. 275-282
[5.]
C. Hoffmann, M. Tiemann, C. Schrader, et al.
AIDS-related B cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping.
Blood, 106 (2005), pp. 1762-1769
[6.]
A. Chadburn, A. Chiu, J.Y. Lee, et al.
Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium Clinical Trials 010 and 034.
J Clin Oncol, 30 (2009), pp. 5039-5048
[7.]
R.F. Little, S. Pittaluga, N. Grant, et al.
Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.
Blood, 101 (2003), pp. 2653-2659
[8.]
R. Madan, R. Gormley, A. Dalau, et al.
AIDS and non-AIDS diffuse large cell lymphomas expressdifferent antigen profiles.
Mod Pathol, 19 (2006), pp. 438-446
[9.]
S.H. Swerlow, E. Campo, N.L. Harris, et al.
WHO Classification of Tumors of Haematopoietic and Lymphoid Tissue.
4th ed, IARC Press, (2008),
[10.]
A predictive model for aggressive non-Hodgkins lymphoma.
The International Non-Hodgkins Lymphoma Prognostic Factors Project.
N Engl J Med, 329 (1993), pp. 987-994
[11.]
D. Camara, S. Stefanoff, A. Pires, et al.
Immunoblastic morphology in diffuse large B-cell lymphoma with a non-germinal center immunophenotypic profille.
Leuk Lymphoma, 48 (2007), pp. 892-896
[12.]
P.N. Meyer, K. Fu, T.C. Greiner, et al.
Immunohistochemical methods for predicting cell of origin and survival in patients with Diffuse large B-cell lymphoma treated with Rituximab.
J Clin Oncol, 29 (2011), pp. 200-207
[13.]
J. Stebbing, B. Gazzard, S. Mandalia, et al.
Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin¿s lymphoma.
J Clin Oncol, 22 (2004), pp. 2177-2183
[14.]
P.Y. Tanaka, L.F. Pracchia, E.E. Calore, et al.
Non-Hodgkin's lymphoma among patients infected with human immunodeficiency virus: the experience of a single center in Brazil.
Int J Hematol, 84 (2006), pp. 337-342
[15.]
P.Y. Tanaka, L.F. Pracchia, M. Bellosso, et al.
A prognostic score for AIDS-related diffuse large B-cell lymphoma in Brazil.
Ann Hematol, 89 (2010), pp. 45-51
Copyright © 2012. Elsevier Editora Ltda.. All rights reserved
Download PDF
The Brazilian Journal of Infectious Diseases
Article options
Tools